LCD 275 Tablet contains a combination of Levodopa 250 mg and Carbidopa 25 mg, formulated for the management of Parkinson’s disease and Parkinsonian syndromes. Levodopa serves as a precursor to dopamine, effectively replenishing diminished dopamine levels in the brain, thereby alleviating symptoms such as bradykinesia, rigidity, and tremors. Carbidopa, a peripheral dopa-decarboxylase inhibitor, enhances the bioavailability of Levodopa by preventing its premature conversion to dopamine outside the central nervous system, which reduces peripheral side effects like nausea and cardiovascular disturbances. This combination allows for lower doses of Levodopa to be administered while maximizing therapeutic efficacy and minimizing adverse effects. LCD 275 Tablet is indicated for symptomatic treatment and is typically initiated at the lowest effective dose, with gradual titration based on clinical response and tolerability. Patients should be monitored for potential side effects including dyskinesias, orthostatic hypotension, and neuropsychiatric symptoms. Caution is advised in individuals with a history of cardiac, hepatic, or renal impairment. Concomitant use with non-selective monoamine oxidase inhibitors is contraindicated. Regular follow-up is essential to optimize dosing and manage long-term therapy challenges associated with Parkinson’s disease progression.